LONDON (Reuters) -Swiss drugmaker Novartis is exploring options to add more medicines to its direct to patient platform that is expected to launch in the U.S. next month, CEO Vas Narasimhan told Reuters in an interview on Tuesday.
“We’re certainly looking to see if we can add other medicines to the platform, but no concrete plans at the moment,” Narasimhan said.
(Reporting by Bhanvi Satija; Editing by Jan Harvey)
